Physician profile
Ramesh Vemuri
NPI 1164508149
$2,544.59
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $261 · 2021: $788 · 2022: $243 · 2023: $245 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $367.14 | 2019-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $340.67 | 2019-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $238.79 | 2019-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $230.40 | 2019-2021 | |
| Alkermes, INC. | $193.59 | 2019-2022 | |
| Lundbeck LLC | $187.74 | 2019-2022 | |
| Abbvie INC. | $179.76 | 2021-2024 | |
| Allergan, INC. | $168.87 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $78.84 | 2019 | |
| Tris Pharma INC | $73.90 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $70.74 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $64.81 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.29 | 2021 | |
| Orexo US, INC. | $43.53 | 2021-2024 | Zubsolv |
| Brainsway USA INC | $43.08 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $32.63 | 2019-2022 | |
| Bausch Health US, LLC | $30.63 | 2019 | |
| Indivior INC. | $28.25 | 2019-2021 | |
| Neos Therapeutics, LP | $24.30 | 2019-2020 | |
| Corium, LLC | $22.05 | 2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $18.56 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.39 | 2020 | |
| Neuronetics, INC. | $12.52 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Vemuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.